Selective BRAF inhibition decreases tumor-resident lymphocyte frequencies in a mouse model of human melanoma
Open Access
- 1 August 2012
- journal article
- Published by Taylor & Francis in OncoImmunology
- Vol. 1 (5) , 609-617
Abstract
The development of targeted therapies and immunotherapies has markedly advanced the treatment of metastasized melanoma. While treatment with selective BRAFV600E inhibitors (like vemurafenib or dabr...Keywords
This publication has 43 references indexed in Scilit:
- Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring V600EBRAFOncogene, 2011
- Molecular determinants of immunogenic cell death elicited by anticancer chemotherapyCancer and Metastasis Reviews, 2011
- Overall survival and PD‐L1 expression in metastasized malignant melanomaCancer, 2010
- CD4+ T Cells Contribute to the Remodeling of the Microenvironment Required for Sustained Tumor Regression upon Oncogene InactivationCancer Cell, 2010
- Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanomaNature, 2010
- RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAFNature, 2010
- Immunogenic and tolerogenic cell deathNature Reviews Immunology, 2009
- BrafV600E cooperates with Pten loss to induce metastatic melanomaNature Genetics, 2009
- Efficient loading of dendritic cells following cryo and radiofrequency ablation in combination with immune modulation induces anti-tumour immunityBritish Journal of Cancer, 2006
- Mutations of the BRAF gene in human cancerNature, 2002